TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24216034
Drug: darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 800/100 mg once daily + two NRTIs
Study: 22278424
Drug: Cabergoline monotherapy
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline monotherapy (0.5 mg once daily for 18 weeks)
Study: 22278424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cabergoline and pegvisomant (10 mg daily for 12 weeks)
Study: 22278424
Drug: Pegvisomant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (10 mg daily after cabergoline withdrawal for 12 weeks)
Study: 15774238
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing vitamin E, selenium, vitamin C, and coenzyme Q10
Study: 12042275
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg/day in two divided doses for 4 weeks)
Study: 9801994
Drug: Intralipid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin)
Study: 9801994
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg, orally, at 0 min and at 210 min)
Study: 26474861
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin–tazobactam (CI)
Study: 26474861
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin–tazobactam (II)
Study: 27533787
Drug: Tedizolid (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedizolid (200 mg once daily for 6 days)
Study: 30242736
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg twice daily for 10 days)
Study: 14722206
Drug: BIIL 284
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIL 284 25 mg
Study: 14722206
Drug: BIIL 284
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIL 284 150 mg
Study: 9459192
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg p.o. once daily
Study: 9459192
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg p.o. once daily
Study: 9459192
Drug: Letrozole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (both doses combined)
Study: 9459192
Drug: Letrozole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (both doses)
Study: 3540835
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy (bovine surfactant, surfactant TA)
Study: 26473443
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued daily activities)
Study: 26215666
Drug: Immediate vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vaccination of eligible adults with single dose vaccination
Study: 23539885
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human follicle-stimulating hormone (rhFSH)
Study: 23539885
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of progesterone in oil (PIO)
Study: 15986229
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg body weight Roc (Roc group)
Study: 15986229
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg succinylcholine (Sux; control group)
Study: 12552184
Drug: Dolasetron 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 12.5 mg intravenous
Study: 12552184
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg intravenous and dexamethasone 4 mg intravenous (control)
Study: 10540047
Drug: Dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium 5000 units s.c. injection administered twice daily for 12 weeks
Study: 1989365
Drug: Control (self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (self‐administered chest physiotherapy alone)
Study: 6815974
Drug: Bupivacaine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 50 mg (another 50 mg 4 h later)
Study: 29589414
Drug: Mepivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (20 mL, 15 mg/mL) for axillary nerve block
Study: 29703335
Drug: GEM-P (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM-P (intravenous gemcitabine 1000 mg/m2 on days 1, 8, and 15, cisplatin 100 mg/m2 on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1-5) every 28 days for four cycles
Study: 29703335
Drug: CHOP (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2 mg] on day 1, and oral prednisolone 100 mg on days 1-5) every 21 days for six cycles
Study: 18090045
Drug: Ritonavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (800 mg)
Study: 18090045
Drug: Amprenavir (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir (1200 mg)
Study: 11697387
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment for unborn children
Study: 9558288
Drug: IFN‐alpha2b (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2b (6 megaunits/m2 thrice weekly for 24 weeks)
Study: 8092901
Drug: H2 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blocker (continuous infusion of ranitidine at 0.25 mg/kg/hr after a loading dose of 0.5 mg/kg) plus antacids
Study: 8092901
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g every 6 hours via nasogastric tube)
Study: 3287907
Drug: Aspirin 648
Normalized name: aspirin 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 648 mg
Study: 19029270
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical and surgical treatment
Study: 15836934
Drug: Stabilisation exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilisation exercises (S&G group)
Study: 15836934
Drug: General exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: General exercise only (G group)
Study: 12207568
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg/day
Study: 12207568
Drug: Policosanol 40
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 40 mg/day
Study: 12207568
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg/day in hypercholesterolaemic patients
Study: 12207568
Drug: Policosanol 40
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 40 mg/day in hypercholesterolaemic patients
Study: 12207568
Drug: Policosanol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (20 and 40 mg/day)
Study: 11235577
Drug: Zeng Sheng-ping
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zeng Sheng-ping (ZSP), 8 tablets, twice a day for 6 months
Study: 8670315
Drug: Chimeric anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-TNF alpha antibody cA2 (1 or 10 mg/kg)
Study: 8670315
Drug: Chimeric anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-TNF alpha antibody cA2
Study: 1984989
Drug: Albuterol 270
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 270 micrograms (three puffs) from a metered dose inhaler
Study: 1984989
Drug: Albuterol 2.5
Normalized name: levalbuterol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 2.5 mg from a saline solution nebulized with an updraft inhaler
Study: 6135076
Drug: Intravenous (3-amino-1-hydroxypropylidene)-1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
Study: 24451697
Drug: Inhaled 1600
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 1600 μg salbutamol
Study: 22130425
Drug: Sublingual Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Immunotherapy followed by Oral Immunotherapy (SLIT/OITB)
Study: 22130425
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OITA)
Study: 22130425
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OITB)
Study: 17646413
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg BID for 3 days, followed by ritonavir 400 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study A)
Study: 17646413
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg BID for 3 days, followed by ritonavir 100 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study B)
Study: 17646413
Drug: Voriconazole coadministered
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole coadministered with high-dose ritonavir
Study: 17646413
Drug: Voriconazole coadministered
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole coadministered with low-dose ritonavir
Study: 17646413
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of voriconazole and ritonavir
Study: 12409716
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy with cyproterone acetate (CPA), 300 mg/day for 12 weeks
Study: 12409716
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy with cyproterone acetate (CPA)
Study: 9793616
Drug: Fast-release test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-release test preparation (Noricaven novo)
Study: 7633141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific therapy)
Study: 3720570
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (10,000 men) received dietary advice, smoking cessation advice, and antihypertensive treatment.
Study: 29482683
Drug: MTA Angelus
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTA Angelus plus IRM capsule
Study: 22615152
Drug: Medial capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial capsule reefing (Group A)
Study: 19931756
Drug: Hypertonic lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic lactate saline (HLS) solution
Study: 15675479
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose mitomycin and epirubicin with caval chemofiltration (CF)
Study: 15675479
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of mitomycin and epirubicin
Study: 9248749
Drug: Gentamicin 3
Normalized name: gentamicin 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 3 mg/kg i.v. bolus and norfloxacin 400 mg twice daily orally from the start
Study: 9248749
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally
Study: 9248749
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with early oral therapy
Study: 4593555
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (aspirin) - single daily dose
Study: 26833624
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray for 14 days
Study: 22886317
Drug: Multidimensional Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Treatment Foster Care
Study: 22265994
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 30 mg intramuscular on days 1, 29, and 57, plus daily immediate-release octreotide 600 μg per day and methylprednisolone on days 1 to 6.
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 25 mg, 50 mg, 100 mg, placebo once daily (OD) for 14 days (Trial 1)
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 25 mg, 50 mg, placebo OD for 14 days (Trial 2)
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 25 mg, 50 mg, 100 mg, placebo single doses (SD) (Trial 3)
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 100 mg SD or placebo for Chinese poor metabolisers (PM) (Trial 3)
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 100 mg OD for 7 days after a 48-hour washout period (Japanese PM, Trial 3)
Study: 29567399
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (various doses)
Study: 28778393
Drug: 4.4 g
Normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 g of fish oil
Study: 12022154
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg for 3 days
Study: 11910595
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg daily) for 8 weeks
Study: 11910595
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy (up to 1.25 mg of conjugated equine estrogens plus 5 mg of medroxyprogesterone acetate daily) for 8 weeks
Study: 11910595
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and hormone therapy (same dosages as above)
Study: 6814669
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg IV)
Study: 31303007
Drug: Intuitive Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intuitive Movement Reembodiment (IMR) program, 10 weekly sessions
Study: 9149578
Drug: Salmeterol, 100
Normalized name: Fluticasone-Salmeterol, 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 100 micrograms twice daily
Study: 2439000
Drug: Intramuscular anti-tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular anti-tetanus serum (ATS)
Study: 25937633
Drug: TM208 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM208 (50 and 150 mg·kg ‐1 ·d ‐1) for 18 days
Study: 25937633
Drug: TM208 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM208 (10, 15 and 20 μmol/L) in vitro
Study: 25937633
Drug: Co-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment with triclosan (inhibitor of sulfonation)
Study: 16500776
Drug: MoodGYM (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodGYM (cognitive behaviour therapy Internet program)
Study: 15611398
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of botulinum toxin type A into the thyroarytenoid muscle(s)
Study: 11014954
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral dose of 150 mg fluconazole for 6 months
Study: 9293648
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline at 7 ml/kg
Study: 9293648
Drug: Isotonic lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic lactated Ringer's solution at 7 mg/kg
Study: 8299637
Drug: Alteplase 100
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 100 mg infused over 3 h
Study: 3571088
Drug: Reinfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinfusion of 600 ml of NaCl-glucose-phosphate solution with approximately 50% hematocrit (n = 6)
Study: 3571088
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (n = 3)
Study: 31638942
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (referral to a community physiotherapy service)
Study: 29186803
Drug: Daily Intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Intake Guides (DIG)
Study: 23513399
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens and medroxyprogesterone (0.625 mg/d plus medroxyprogesterone 5 mg/d for 10 days)
Study: 21546627
Drug: CEM‐102 (fusidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEM‐102 (fusidic acid) administered in single, multiple, and loading doses
Study: 21546627
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of CEM‐102
Study: 15523294
Drug: Low-dose nesiritide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nesiritide (0.015 microg/kg/min)
Study: 15523294
Drug: High-dose nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose nesiritide (0.03 microg/kg/min)
Study: 7506144
Drug: Seaprose S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaprose S 60 mg/day
Study: 3101609
Drug: LNT injection
Normalized name: NIACINAMIDE 1.5 g in 50 g / TOCOPHEROL 1.5 g in 50 g / 4-BUTYLRESORCINOL 2.5 g in 50 g / ARBUTIN 3.5 g in 50 g TOPICAL CREAM [Lntimate Area]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNT injection following surgical therapy (Ax + Ox)
Study: 3101609
Drug: LNT injection
Normalized name: NIACINAMIDE 1.5 g in 50 g / TOCOPHEROL 1.5 g in 50 g / 4-BUTYLRESORCINOL 2.5 g in 50 g / ARBUTIN 3.5 g in 50 g TOPICAL CREAM [Lntimate Area]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNT injection
Study: 26673586
Drug: Prophylactic nebulised
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic nebulised heparin (50,000 U)
Study: 22184381
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus vandetanib (100 mg)
Study: 22184381
Drug: Single-agent vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent vandetanib (after crossover)
Study: 19949861
Drug: Internal urethrotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal urethrotomy with submucosal injection of triamcinolone (40 mg)
Study: 17967221
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (SR) treatment for 3 years
Study: 16002025
Drug: LAAM (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (100, 100, 130 mg/MWF) with contingency management (CM)
Study: 16002025
Drug: LAAM (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (100, 100, 130 mg/MWF) without CM
Study: 16002025
Drug: LAAM (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (30, 30, 39 mg/MWF) with CM
Study: 16002025
Drug: LAAM (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (30, 30, 39 mg/MWF) without CM
Study: 16002025
Drug: LAAM (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (100, 100, 130 mg/MWF) with CM
Study: 11833838
Drug: Combination hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (HC/IB)
Study: 11833838
Drug: Combination oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oxycodone 5 mg and acetaminophen 325 mg (OX/AC)
Study: 10189543
Drug: Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin combined with standard diet and exercise recommendations
Study: 2373136
Drug: Terguride 50
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride 50 micrograms i.v. dose
Study: 2373136
Drug: Terguride 250
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride 250 micrograms oral treatment
Study: 2373136
Drug: Terguride 500
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride 500 micrograms oral treatment
Study: 2373136
Drug: Terguride 750
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride 750 micrograms oral treatment
Study: 2373136
Drug: Terguride (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terguride (all doses)
Study: 7295072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anticholinergics, sulphoglicopeptide and sucralfate
Study: 9842807
Drug: Information +
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information + modeling + coping-based program (OR tour + videotape + child-life preparation)